메뉴 건너뛰기
Nature Biotechnology
Volumn 22, Issue 4, 2004, Pages 461-463
US courts struggle with new patent infringement standards

(1)  Jones, Phill a  

a NONE
Author keywords

[No Author keywords available]
Indexed keywords

AMFEBUTAMONE; BACILLUS THURINGIENSIS TOXIN; ERYTHROPOIETIN; GENERIC DRUG; HYDROXYPROPYLCELLULOSE; HYDROXYPROPYLMETHYLCELLULOSE; POLYVINYL ALCOHOL;
EID: 1842477421     PISSN: 10870156     EISSN: None     Source Type: Journal    
DOI: 10.1038/nbt0404-461     Document Type: Review
Times cited : (1)
References (11)
  • 1
    • 0036690292 scopus 로고    scopus 로고
    • Festo and the US Supreme Court: Be careful what you wish for
    • Gogoris, A.C. & Lee, S.S. Festo and the US Supreme Court: be careful what you wish for. Nat. Biotechnol. 20, 845-846 (2002).
    • (2002) Nat. Biotechnol. , vol.20 , pp. 845-846
    • Gogoris, A.C.1    Lee, S.S.2
  • 2
    • 1842625071 scopus 로고    scopus 로고
    • Amgen, Inc. v. Hoechst Marion Roussel, Inc., 287 F.Supp.2d 126 (D. Mass. 2003)
    • Amgen, Inc. v. Hoechst Marion Roussel, Inc., 287 F.Supp.2d 126 (D. Mass. 2003).
  • 3
    • 1842573062 scopus 로고    scopus 로고
    • Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 234 F.3d 558 (Fed. Cir. 2000)
    • Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 234 F.3d 558 (Fed. Cir. 2000).
  • 4
    • 1842573059 scopus 로고    scopus 로고
    • Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002)
    • Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 535 U.S. 722 (2002).
  • 5
    • 1842625074 scopus 로고    scopus 로고
    • Glaxo Wellcome, Inc. v. Eon Labs Mfg., 2002 U.S. Dist. LEXIS 14923 (S.D.N.Y. Aug. 13, 2002)
    • Glaxo Wellcome, Inc. v. Eon Labs Mfg., 2002 U.S. Dist. LEXIS 14923 (S.D.N.Y. Aug. 13, 2002).
  • 6
    • 1842625069 scopus 로고    scopus 로고
    • Glaxo Wellcome, Inc. v. Impax Labs., Inc., 220 F.Supp.2d 1089 (N.D. Cal. 2002); affirmed by Glaxo v. Impax, 2004 U.S. App. LEXIS 1324 (Fed. Cir. Jan. 29, 2004)
    • Glaxo Wellcome, Inc. v. Impax Labs., Inc., 220 F.Supp.2d 1089 (N.D. Cal. 2002); affirmed by Glaxo v. Impax, 2004 U.S. App. LEXIS 1324 (Fed. Cir. Jan. 29, 2004).
  • 7
    • 1842468533 scopus 로고    scopus 로고
    • SmithKline Beecham Corp. v. Excel Pharm., Inc., 214 F.Supp.2d 581 (E.D. Va. 2002); vacated and remanded by SmithKline v. Excel, 2004 U.S. App. LEXIS 1323 (Fed. Cir. Jan. 29, 2004)
    • SmithKline Beecham Corp. v. Excel Pharm., Inc., 214 F.Supp.2d 581 (E.D. Va. 2002); vacated and remanded by SmithKline v. Excel, 2004 U.S. App. LEXIS 1323 (Fed. Cir. Jan. 29, 2004).
  • 8
    • 1842573063 scopus 로고    scopus 로고
    • Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 344 F.3d 1359 (Fed. Cir. 2003)
    • Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co., 344 F.3d 1359 (Fed. Cir. 2003).
  • 9
    • 1842573060 scopus 로고    scopus 로고
    • Ranbaxy Pharmaceuticals, Inc. v. Apotex, Inc., 350 F.3d 1235 (Fed. Cir. 2003)
    • Ranbaxy Pharmaceuticals, Inc. v. Apotex, Inc., 350 F.3d 1235 (Fed. Cir. 2003).
  • 10
    • 1842573061 scopus 로고    scopus 로고
    • Mycogen Plant Sci. v. Monsanto Co., 2004 U.S. App. LEXIS 3001 (Fed. Cir. Feb 20, 2004)
    • Mycogen Plant Sci. v. Monsanto Co., 2004 U.S. App. LEXIS 3001 (Fed. Cir. Feb 20, 2004).

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.